We are currently seeking a Senior Research Associate, Primary Cell Editing who will be conducting gene editing translational research within the growing Blood Disorders group at Mammoth Biosciences. The successful candidate will make significant contributions to several projects within Mammoth’s early-stage therapeutics pipeline. Specifically, the candidate will culture and characterize primary cells using a variety of established methods. The candidate will receive hands-on training in the use of Mammoth’s proprietary CRISPR nuclease systems for therapeutic gene editing.KEY RESPONSIBILITIES
- Gene edit primary cells using Mammoth CRISPR systems
- Maintain primary cells in tissue culture
- Characterize edited cells by genomic and biochemical techniques including ddPCR/qPCR, western blot, and flow cytometry
- BS in Biology, Chemistry, Biochemistry, Biotechnology or related discipline
- 3+ years of post graduate-research experience
- At least one year of industry research experience
- Experience with standard molecular biology techniques including PCR, ddPCR or qPCR
- Experience with standard molecular phenotyping techniques including western blot, ELISA or flow cytometry
- Experience in gene editing
- Experience in culture of primary human cells
- Experience in next-generation sequencing library preparation
- A foundation in experimental documentation and data presentation
- Excellent oral and written communication skills
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo
and ex vivo
therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.